Skip to main content
spacbrain

ARYA Sciences Acquisition Corp IV

ARYD · Nasdaq

Trust settledAdagio Medical, Inc. · Finished

NO ACTION REQUIRED

Nothing left to do

The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.

Cash at settlement

no closing figure

No cash-per-share figure was filed for this vehicle before it finished.

Last close

no quote on file

Daily close

Nothing left to claim

this vehicle finished

There is nothing to hand back: holders who wanted cash elected it at the vote, and the rest became shares in the buyer.

Read what happened to the cash

The floor

Trust settled

This SPAC has finished — its trust was paid out or used to close the deal, so there is nothing left to redeem

Read the reasoning behind this verdict

No price history on file yet — daily closes accumulate from the market data feed.

Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.

SpacBrain’s read

Trust settled

The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

In plain terms

What it is
A SPAC, listed on Nasdaq in March 2021.
What it's doing now
It agreed in November 2021 to buy Adagio Medical, Inc., a Medical device company company. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
What you should know
This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.

At a glance

Where it stands
Closed (deSPAC)
The business it bought
Adagio Medical, Inc.
Industry
Medical device company
Deal value
not stated in the filings we hold
announced 1 November 2021
Price vs cash at settlement
no live price on file
Cash in trust when it settled
not yet extracted into a snapshot — the filings below may state it
the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
IPO
1 March 2021
size not on file · 100.0% of each $10 unit into trust
Headquarters
51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY, 10003
registered in the Cayman Islands
Lead underwriter
not extracted from the prospectus yet
Key officers
Wider Todd (Director) · Stone Adam Leo (Chief Executive Officer) · HENDERSON MICHAEL THOMAS (Director)
Listed securities
ARYD common
Cash held per sharenot filed for this window

This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.

Next date that mattersno dated event on file

Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.

Yield to redemption

Nothing left to redeem — no yield to compute.

This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.

What happened to the cash

The reasoning behind the verdict above, in the order the filings establish it.

  1. The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

What has happened, and what is coming

3 dated milestones

Every dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.

  1. 1 March 2021IPOpassed

    IPO size not on file

  2. 1 November 2021Deal announcedpassed

    Combination with Adagio Medical, Inc.

  3. 27 February 2024Extension votepassed0001140361-24-009514opens on sec.gov in a new tab

The deal

terms as filed

What it is buying, on what terms, and how much of the combined company new shares take from you.

The score

deterministic, from filed fields

ARYD is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.

Asymmetric return scoreNeither a price nor a cash-per-share figure is on file for this vehicle, and the score is a ratio between the two. Nothing is estimated to fill the gap.

The score is only published for names that carry both a price and a filed cash-per-share figure — 292 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.

See the names that are scored, and how

The company

from SEC filings
Read the full profile

ARYA Sciences Acquisition Corp IV was a blank-check company whose common stock traded on Nasdaq under the ticker ARYD. The company priced its initial public offering on March 1, 2021, pursuant to a 424B prospectus, and was assigned SEC CIK 0001838821 with SIC industry code 6770. The vehicle completed a business combination and no longer files as a standalone registrant. Its closure is evidenced by Form 25 filed on July 31, 2024, under which its Class A Ordinary Shares came to evidence other securities in substitution therefor, and by an 8-K filed by successor registrant Adagio Medical Holdings, Inc. (ADGM) on July 26, 2024, reporting completion of the acquisition.

Material findings

from the full read of every filing

Every document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.

  • DEFM14A15 July 20240001140361-24-033082opens on sec.gov in a new tab

    The disclosed redemption value of approximately $11.54 per Class A ordinary share as of July 8, 2024 sets the trust floor a holder gives up by rolling into the deal. The financing structure is the risk: $55.6 million of PIPE includes $23 million contributed as existing convertible notes rather than new cash, so the actual money arriving at closing is materially less than the headline. Non-redemption commitments from PIPE investors who bought in the open market are a standard device to keep trust cash in the deal, and they signal the sponsor expected heavy redemptions.

  • DEF 14A10 February 20230001140361-23-005984opens on sec.gov in a new tab

    The convertibility feature is the term that costs public holders: the sponsor's extension funding can be turned into equity on closing rather than repaid in cash, so the money that props up the trust today becomes dilution tomorrow. Total committed support is $1,680,000 across a possible twelve months, modest against the trust. Board discretion over each monthly step after June 2, 2023 means this meeting is the last redemption decision holders control, and the alternative the company names explicitly is forced liquidation at trust value.

  • S-41 November 20210001140361-21-036018opens on sec.gov in a new tab

    Every one of the 19,186,500 shares registered here is ARYA's own capital converting by operation of law in the domestication: 14,950,000 Class A ordinary shares from the IPO, 499,000 private placement Class A ordinary shares and 3,737,500 Class B ordinary shares. Nothing is registered for the Amicus side, so the fee table measures the SPAC, not the target. The financing sits outside it: 20,000,000 New Caritas Class A shares at $10.00 for $200 million of PIPE proceeds, $50 million from the Perceptive PIPE Investor, against a trust of approximately $149,519,811 at June 30, 2021.

Filings

live EDGAR feed

Everything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.

Show the other 10 filings
  • 431 July 20240001140361-24-035172opens on sec.gov in a new tab
  • 431 July 20240001140361-24-035170opens on sec.gov in a new tab
  • 431 July 20240001140361-24-035169opens on sec.gov in a new tab
  • 431 July 20240001140361-24-035164opens on sec.gov in a new tab
  • 25-NSE31 July 20240001354457-24-000541opens on sec.gov in a new tab
  • 42526 July 20240001140361-24-034410opens on sec.gov in a new tab
  • 8-K26 July 20240001140361-24-034408opens on sec.gov in a new tab
  • 8-K23 July 20240001140361-24-033881opens on sec.gov in a new tab
  • 42523 July 20240001140361-24-033882opens on sec.gov in a new tab
  • DEFM14A15 July 20240001140361-24-033082opens on sec.gov in a new tab

    What changed: ARYA Sciences Acquisition Corp IV filed its merger proxy for the business combination with Adagio under an agreement dated February 13, 2024, amended June 25, 2024. The Perceptive PIPE Investor will contribute $15,000,000 of Adagio convertible notes purchased under an April 4, 2023 note purchase agreement plus an $8,000,000 convertible note. The PIPE financing totals $55,600,000, including $2,500,000 of open-market Class A purchases valued at about $2,542,710 on July 8, 2024 at a redemption value of roughly $11.54 per share, producing about 405,086 shares and 343,070 base warrants. Why it matters: The disclosed redemption value of approximately $11.54 per Class A ordinary share as of July 8, 2024 sets the trust floor a holder gives up by rolling into the deal. The financing structure is the risk: $55.6 million of PIPE includes $23 million contributed as existing convertible notes rather than new cash, so the actual money arriving at closing is materially less than the headline. Non-redemption commitments from PIPE investors who bought in the open market are a standard device to keep trust cash in the deal, and they signal the sponsor expected heavy redemptions.

    minimum cash conditionnothing moved · 1 with no prior record of ours
    Minimum cash condition
    not previously extracted$50.0M

    SpacBrain reads this as the min-cash condition binds at $50,000,000.

    The clause …“capitalization of ListCo as of the Closing; (e) the removal of a minimum cash condition, and inclusion of a minimum gross financing proceeds condition of $50 million; (f) each of the Sponsor and Adagio being entitled to”…

    Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.

The record

The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.

Show the reference detail

Unit structure

Cash in trust at IPO$10.00

from 424B4 0001140361-21-006658

Trading & liquidity

Average daily volume (20d)no volume reported on the bars we hold
Average daily $ volumeneeds both volume and a live price
Range over the bars heldnot enough price history
Total cash in trustthe trust total is not in the last XBRL stamp

Company profile

Industry (SIC)Blank Checks (6770)
Registered inthe Cayman Islands
Exchange · CIKNasdaq · 0001838821

All filings on EDGARopens on sec.gov in a new tab

Directors & officers

Institutional holders

from SC 13G/13D

Funds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.

Show the declared stakes

13 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.

One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.

Sources on file

harvested pages, kept in full

Every public page we have read about this company, stored in full so a source can never go missing.

Show the sources

38 full SEC filing texts archived — searchable, never lost.

In plain English

tap a term to open it

Every piece of jargon this page could have used, and what it actually means.

Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected

A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.

Redemption deadlinethe last day to hand shares back for cash

Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.

Broker action datethe day your broker needs the instruction — earlier than the official date

Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.

Cash in trust / trust per sharethe cash the company is holding for each public share

Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.

Trust discountbuying below the cash held for you

Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.

Dilutionhow much of the company new shares take from you

Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.

Pro-forma equitywhat the company is valued at once the deal closes

The combined company's equity value assuming the announced terms and the redemptions that have actually happened.

ARShow much upside you get per unit of downside

SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.

De-SPACthe day the SPAC becomes the real company

The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.

Outside datethe contractual long-stop for closing the deal

A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.

Accession numberthe SEC's unique id for one filing

Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.

Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since

A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.

Ask the brain

from its filings
Data provenance & audit trail4 internal entries

Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.

ARYD — company record
UNIVERSE-HISTORY2026-08-16

admitted from the HISTORICAL census (EDGAR's SIC 6770 registrant list, walked in full: 3,325 registrants, 1,167 of which ever priced an IPO). The live discovery job cannot reach this registrant — it reads the filing tape, and this one stopped filing. Admission rule: src/lib/universe-admit.ts. SIC 6770 (Blank Checks); 424B 0001140361-21-006658 priced 2021-03-01; common ticker ARYD off 8-K 0001140361-24-034408 (2024-07-26); lifecycle EXITED. Ending PROVEN, not inferred: CLOSED per Form 25 0001354457-24-000541 (2024-07-31) — Form 25 filed under 17 CFR 240.12d2-2(a)(3) — the rule for securities that "have come to evidence other securities in substitution therefor", i.e. the shares became the successor's (class: Class A Ordinary Shares); the successor registrant Adagio Medical Holdings, Inc. (ADGM) (CIK 0002006986) filed an 8-K carrying item 2.01 (Completion of Acquisition) naming "ARYA Sciences Acquisition Corp IV" — the SPAC merged into a new registrant and so filed no closing report of its own. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

Deal — Adagio Medical, Inc.
DEAL-TARGET2024-07-15

AI-extracted target (z-ai/glm-5.2, conf 0.95)

BACKFILL2026-08-26

target recovered for a completed de-SPAC

PROFILE-STUB2026-08-27

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

Back to the screenerVault note